Bacterial News and Research

RSS

Modulating body's inflammatory response may help fight serious infection

Treating virulent influenza, sepsis, and other potentially deadly infections long has focused on looking for ways to kill viruses and bacteria. But new research from the University of Utah and Utah State University shows that modulating the body's own overeager inflammatory response to infection may help save more lives.

18 Mar 2010

New book exposes the ignored causes of three major life-threatening and chronic diseases

In his newest book, "Overlooked Causes and the Prevention: Cancer, Cardiovascular Heart Disease, Multiple Sclerosis" (published by AuthorHouse), author Arthur Douglass Alexander III exposes, delineates and documents the sometimes overlooked and often ignored causes of three major life-threatening and chronic diseases: cancer, cardiovascular disease and multiple sclerosis.

18 Mar 2010

Stress during pregnancy may raise infant’s risk to asthma and allergy

Stress during pregnancy may raise the risk of asthma in offspring, according to researchers at Brigham and Women's Hospital and Harvard Medical School in Boston.

18 Mar 2010

Restoring immune function in HIV patients: Therapies targeting PD-1 and IL-10 molecules needed

New research conducted by the scientific director for VGTI Florida and his colleagues at the University of Montreal, in collaboration with scientists from the NIH and the McGill University Hospital center, may soon lead to an expansion of the drug arsenal used to fight HIV. The research sheds new light on how HIV gradually weakens the body’s immune system and highlights the need for new research into therapies that will target the chain of events that cause the progression of the disease.

17 Mar 2010

IDSA calls for global commitment to develop 10 new antibiotics by 2020

As the deaths and suffering caused by antibiotic-resistant bacterial infections continue to rise around the world, the Infectious Diseases Society of America (IDSA) is urging a global commitment to develop 10 new antibiotics by 2020, known as the 10 x '20 initiative, to address this public health crisis and safeguard patients' health.

17 Mar 2010

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.

16 Mar 2010

Research reveals molecular mechanism of DNA repair

New research led by scientists at the University of Essex has given an insight into how the body finds damage in the DNA code to repair it.

16 Mar 2010

Enzo Biochem to market MultiGEN’s multiplex DNA sequencing based diagnostic tests in state of New York

Enzo Biochem, Inc. today announced that it has entered into an agreement with MultiGEN Diagnostics Inc., of San Diego, California, for exclusive rights to market MultiGEN’s unique diagnostic tests based on multiplex DNA sequencing, in the state of New York. In addition, Enzo has been granted marketing rights for other non-exclusive territories in United States.

15 Mar 2010

iGPS urges the U.S. Senate to mandate latest tracking technology in legislation to prevent foodborne illnesses

Cost-effective technology that allows products to be traced through the U.S. supply chain might have helped contain the spread of hydrolyzed vegetable protein products contaminated with Salmonella, Intelligent Global Pooling Systems announced today. iGPS urged the U.S. Senate to mandate the latest tracking technology in legislation pending to overhaul the nation's food safety law.

15 Mar 2010

Study finds new way to reduce risk of life-threatening bloodstream infections in newborns

Hospitals may reduce the risk of life-threatening bloodstream infections in newborns with peripherally inserted central venous catheters by replacing the device every 30 days or so, according to a new Johns Hopkins Children's Center study.

15 Mar 2010

Antibiotics lower risk of developing gastric cancer

Helicobacter pylori, a bacterium found in about 50% of humans worldwide, can cause stomach ulcers and, in extreme cases, gastric cancer. In an article for F1000 Medicine Reports, Seiji Shiota and Yoshio Yamaoka discuss the possible eradication of H. pylori infections

12 Mar 2010

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has presented for the first time to the medical community data from its Phase 1B clinical study with its defensin-mimetic antibiotic compound, PMX-30063.

12 Mar 2010

Advaxis develops long-term, room temperature, storage-stable form of its vaccines

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company has developing a long-term, room temperature, storage-stable form of its vaccines. This would replace the current requirement to keep the product frozen at -70o C before use.

12 Mar 2010

bioMerieux introduces FDA cleared chromID VRE for detecting Enterococcus faecium and Enterococcus faecalis

bioMerieux – a world leader in the field of in vitro diagnostics – today announced the launch of the first Food and Drug Administration (FDA) cleared chromID™ VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in stool specimens.

12 Mar 2010

FDA provides guidance on Restanza clinical program in treatment of CABP

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that the U.S. Food and Drug Administration has provided guidance on the clinical program required to assess the approvability of Restanza™ (cethromycin), a novel oral once-a-day antibiotic, in the treatment of outpatient community acquired bacterial pneumonia (CABP) as well as biodefense indications including anthrax, plague and tularemia.

11 Mar 2010

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2009.

11 Mar 2010

Fewer injections to treat neutropenia in childhood cancer patients

For patients like 10-year-old Sabrina Jo Spence, new research led by St. Jude Children's Research Hospital investigators meant fewer injections to combat the drop in white blood cells following her recent chemotherapy.

11 Mar 2010

Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide

Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study with the company's intravenous formulation of CEM-101 in mid-2010.

10 Mar 2010

Growing human therapeutic proteins in algae can help reduce cancer treatment cost

Pharmaceutical companies could substantially reduce the expense of costly treatments for cancer and other diseases produced from mammalian or bacterial cells by growing these human therapeutic proteins in algae-rapidly growing aquatic plant cells that have recently gained attention for their ability to produce biofuels.

9 Mar 2010

Advaxis confirms long-term stability of its first clinical formulation of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has confirmed the long-term stability of its first clinical formulation of ADXS11-001, the Company’s lead immunotherapeutic.

9 Mar 2010

Bacterial News and Research

Modulating body's inflammatory response may help fight serious infection

New book exposes the ignored causes of three major life-threatening and chronic diseases

Stress during pregnancy may raise infant’s risk to asthma and allergy

Restoring immune function in HIV patients: Therapies targeting PD-1 and IL-10 molecules needed

IDSA calls for global commitment to develop 10 new antibiotics by 2020

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

Research reveals molecular mechanism of DNA repair

Enzo Biochem to market MultiGEN’s multiplex DNA sequencing based diagnostic tests in state of New York

iGPS urges the U.S. Senate to mandate latest tracking technology in legislation to prevent foodborne illnesses

Study finds new way to reduce risk of life-threatening bloodstream infections in newborns

Antibiotics lower risk of developing gastric cancer

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

Advaxis develops long-term, room temperature, storage-stable form of its vaccines

bioMerieux introduces FDA cleared chromID VRE for detecting Enterococcus faecium and Enterococcus faecalis

FDA provides guidance on Restanza clinical program in treatment of CABP

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

Fewer injections to treat neutropenia in childhood cancer patients

Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide

Growing human therapeutic proteins in algae can help reduce cancer treatment cost

Advaxis confirms long-term stability of its first clinical formulation of ADXS11-001

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News